Cowellmedi Co., Ltd. is a prestigious multinational company, leader in biotechnologies, which produces:

  • State-of-the-art dental implants
  • Bone Graft Biomaterials
  • Specific Dental Surgical Instruments

Headquartered in Busan, South Korea, Cowellmedi was the first ever company in the world to market Growth Factors and has more than 40 connections worldwide.

Cowellmedi was the first company to locate the production of dental implants in Korea in 1994.

Originally founded as Asrahi Medical in 1998, it immediately began to play a pioneering and prominent role in the Korean and global implant industry.



The company has always focused on research and innovation, and in this regard, it has developed products of undisputed quality and FDA certified. Since its conversion in 2000 to Cowellmedi Corporation, it has had a large number of patents both in Korea and around the world.


It must be emphasized:

  1. the development for the first time of a protein regarding growth factors (E.rhBMP-2);
  2. the application of improved roughness to implant surface treatments (which gives to the system a unique feature of wettability and hydrophilicity as a result of a roughening process patented by Cowellmedi Co., Ltd.).

Thanks to the acknowledgments and certifications received in Korea and the United States for the rhBMP-2 and regarding the implant surface coating technology, Cowellmedi is today considered a world leader by both the scientific and dental communities, as a manufacturer of cutting-edge and next-generation dental implants.

Cowellmedi has distinguished itself for being the number one among biotechnology companies, based on the greater experience in production and research regarding dental implants and growth factors (E.rhBMP-2) having a philosophy constantly oriented to research and development.


Cowellmedi Co., Ltd. has more than 40 patents, including one related to implant surface coating with BMP-2 in the United States and Korea as well as those mentioned on the right:

  • The MFS KIT (Multi-Functional Sinus KIT) of 18-01-2017 is developed
  • Kit for tissue repair composed of BMP-2 and biomaterial graft (10-13777558) of 18.03.2014
  • The SLA-SH surface treatment was developed for the first time in 02-12-2014
  • Dental implants manufactured with titanium alloy bases (10-1184623) dated 14-09-2012
  • The manufacture of a graft biomaterial based on beta tricalcium phosphate of granular type, with a volumetric concentration that mimics the trabecular bone structure (10-1108431) of 18-01-2012
  • Dental implant coated with recombinant bone morphogenetic protein (US 7,879,092, B2) dated 01-02-2011
  • Abutment for increasing bone volumes (10-0969889) dated 06-07-2010
  • for locking the bone graft (10-09362292) dated 01-04-2010


In addition to the patents listed above and the specific patents on implant coating obtained in Korea and the USA, Cowellmedi Co., Ltd. has obtained the following certifications: